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ABSTRACT
Introduction: X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal metabolic 
disorder associated with mutations in the ATP-binding cassette sub-family D member1 
(ABCD1) gene. Practically all male patients with X-ALD develop adrenocortical 
insufficiency during childhood and progressive myelopathy and peripheral neuropathy in 
adulthood. However, some male patients develop a fatal cerebral demyelinating disease 
named cerebral adrenoleukodystrophy. Although the exact mechanisms underlying 
brain damage in X-ALD are still poorly elucidated, it is known that hexacosanoic acid 
(C26:0) accumulation represents a hallmark in the pathogenesis of this disease. In this 
study, we examined whether an overload of C26:0 injected in Wistar rats was capable 
of causing behavioral changes in these animals.
Methods: Egg lecithin in ethanol was dried under a nitrogen stream and mixed with C26:0 
methyl ester. Male Wistar rats at 2-3 weeks of age were obtained from Universidade 
Federal do Rio Grande do Sul (UFRGS), divided into 8 groups, and submitted to an 
open field test. We then analyzed line crossings (locomotion and exploration), rearing 
(orienting and investigatory responses), grooming (anxiety manifestation), and latency 
to move for each animal.
Results: Animals subjected to C26:0 administration presented fewer crossings and 
rearing episodes and a higher latency to move 45 minutes after C26:0 injection. 
The present work yields experimental evidence that C26:0, the main accumulated 
metabolite in X-ALD, can cause behavioral alterations in rats such as the impairment 
of locomotion and exploratory capabilities, as well as a reduction in orienting and 
investigatory responses.
Conclusion: Although our results are preliminary, they are extremely important for 
future studies that investigate C26:0 accumulation and locomotor impairment in 
patients with X-ALD.
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INTRODUCTION
X-linked adrenoleukodystrophy (X-ALD) is a progressive neurodegenerative 
disease with an estimated incidence of 1 in 17 000 that has been diagnosed in 
all geographic regions and ethnic groups1. This disease is caused by mutations 
in the ABCD1 gene; this gene encodes the peroxisomal membrane protein 
ALDP, which is involved in the transmembrane transport of very long-chain 
fatty acids (VLCFA) into peroxisomes2. As a consequence of this mutation, 
VLCFAs (mainly tetracosanoic acid [C24:0] and hexacosanoic acid [C26:0]) 
accumulate in the plasma and tissues, including the white matter of the brain, 
spinal cord, and adrenal cortex3,4.
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The disease presents great phenotypic variability, 
ranging from the rapidly progressive cerebral form 
that leads to total disability within the first decade 
to the milder adrenomyeloneuropathy (AMN), 
which is compatible with survival until the eighth 
decade after disease onset. The literature describes 
7 main phenotypes in hemizygous male patients: 
the childhood cerebral form (CCER), juvenile cerebral 
form, adult cerebral form, AMN, Addison’s only, 
olivopontocerebellar, and asymptomatic forms5.
The cerebral form is the most progressive, severe, 
and devastating phenotype of this disease, and CCER 
is the most frequent form, with an insidious onset. 
These patients seem unaffected until the age of 
2-10 years, when adrenal insufficiency, progressive 
neurological dysfunction (including problems with 
walking and locomotion), and cognitive deficits 
involving visuospatial and visuomotor functions, as 
well as attention and reasoning, start to develop. 
Symptoms depend on the site of the initial lesions. 
In elementary school-aged boys, the first symptoms 
are usually cognitive deficits and behavioral problems 
manifesting as a decline in school performance1. 
These early clinical symptoms are often misdiagnosed 
as attention deficit hyperactivity disorder and can 
delay the diagnosis of CCER. Other symptoms 
start to appear as the disease progresses, such 
as withdrawn or hyperactive behavior, apraxia, 
astereognosis, hearing impairment, decreased 
visual acuity, hemiparesis or spastic tetraparesis, 
cerebellar ataxia, and seizures. Death usually occurs 
2 to 4 years after symptom onset5,6.
“Pure” AMN (without cerebral involvement) is a 
noninflammatory distal axonopathy that involves 
the long tracts of the spinal cord and, to a lesser 
extent, the peripheral nerves. Patients present 
paraparesis, sphincter disturbances, sensory changes, 
incoordination, pain, and impotence. The age of 
onset of AMN varies between the second and the 
fourth decade of life, and cerebral changes develop 
in approximately half of the patients. Patients with 
cerebral AMN can present dementia, behavioral 
disturbances, psychosis, epilepsy, aphasia, visual 
loss, and bulbar palsy7. Patients with the Addison’s 
only form of the disease (10% to 20% of X-ALD 
patients) have primary adrenal insufficiency without 
evidence of nervous system involvement, but are 
at high risk of eventually developing AMN. Some 
patients with the genetic defect are free of adrenal 
insufficiency and neurologic disabilities despite their 
high levels of saturated VLCFA; these are classified 
as asymptomatic and present a high risk of developing 
the CCER phenotype8.
Our research group observed changes in glial cell 
metabolism with the addition of C26:0 in cell culture9, 
but the behavioral effect of the administration of C26:0 
in rats has not yet been described in the literature. 
Therefore, we aimed to investigate whether an 
overload of C26:0, achieved through intraperitoneal 
injection in wild type Wistar rats, causes behavioral 
changes in these animals.
METHODS
Vesicle preparation
Ethanol containing 8 mg of egg lecithin (Sigma-
Aldrich, St. Louis, USA) was dried under a nitrogen 
stream and mixed with 4 mg of C26:0 methyl ester 
(Sigma-Aldrich). The sample was suspended in 2.5 mL 
of sterile water and then sonicated with a microtip 
(Sonicator Ultrasonic Processor XL – Misonix Inc., 
Famingdale, USA). The same procedure, without 
the C26:0 methyl ester, was performed to obtain 
pure lecithin vesicles used as the vehicle control10,11.
Animals
Male Wistar rats were obtained from the central 
vivarium at Universidade Federal do Rio Grande 
do Sul (UFRGS) at 2-3 weeks of age. The animals 
were immediately housed in polypropylene boxes 
measuring 41 × 34 × 16 cm (up to 4 animals per cage) 
and kept in a 12 hour light-dark environment at 
23 ± 1°C. The animals had ad libitum access to 
pelleted chow and water. The experiments were 
performed in accordance with the Guide for the Care 
and Use of Laboratory Animals, DHEW Publication 
No. (NIH) 80-23 (1985) and were approved by the 
local Ethics Committee at UFRGS.
Experimental groups
The animals were divided into 8 experimental 
groups (6 animals in each group): Basal control 
(without injection); saline control (received 100 µL 
of 0.9% sodium chloride); lecithin vesicle 15 min, 
45 min, and 60 min (received 100 µL of lecithin 
vesicle and were sacrificed 15, 45, or 60 minutes after 
injection, respectively); vesicle + C26 15 min, 45 min, 
and 60 min (received 100 µL of vesicles with C26:0 
methyl ester at a final concentration of 4 mM and 
were sacrificed 15, 45, or 60 minutes after injection, 
respectively). All treatments were administered by 
intraperitoneal injection.
Behavioral test
Rats were submitted to a behavioral task using 
an open field test and sacrificed 5 minutes later. The 
test used an acrylic box whose bottom was divided by 
black lines into 12 equisized quadrants; animals were 
placed on one specific quadrant, facing the box wall, 
and were left to freely explore the box for 5 minutes. 
The open field apparatus was a 40 cm × 60 cm linoleum 
floor area surrounded on three sides by a 60 cm 
plywood wall and on the other, by a 60 cm glass wall. 
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Line crossings (locomotion and exploration), rearing 
(orienting and investigatory responses), grooming 
(anxiety manifestation), and latency to move were 
analyzed for each rat12. After each test, the floor was 
cleaned with water and 70% ethanol to avoid a potential 
excitatory effect produced by urine or fecal residues.
Brain microdissection and tissue preparation
At the end of the study, the animals were 
sacrificed by decapitation and the brains were 
immediately removed and placed on a cold plate. 
The whole brains were dissected and chilled 
until homogenization in 1:5 (w/v) saline solution 
(0.9% NaCl). The homogenate was centrifuged at 
800 × g for 10 min at 4°C, and the supernatant was 
used for determining C26:0 concentrations.
Fatty acid analysis
C26:0 was analyzed according to Moser and 
Moser13. The procedure consisted in the preparation of 
a total lipid extract, which was treated with methanolic 
HCl (3N) for the production of fatty acid methyl esters; 
these were then purified by thin-layer chromatography. 
The purified esters were extracted with hexane and 
analyzed by gas chromatography. We used a Varian 
gas chromatographer (Agilent Technologies, Santa 
Clara, USA) with an HP-5 column (5% methylphenyl 
silicone, 0.33 mm film thickness, 0.2 mm inner diameter 
and 25 m column length), a flame ionization detector, a 
split/splitless injector, and helium as the mobile phase. 
C26:0 concentrations were expressed in μmol/L. 
Heptacosanoic acid was used as an internal standard.
Statistical analysis
Results were expressed as mean ± standard error of 
the mean (SEM). Comparisons between mean values 
were made using one-way analysis of variance (ANOVA), 
followed by a Tukey’s post-hoc test. p values < 0.05 
were considered significant. GraphPad Prism version 
5.0 (GraphPad Software Inc., San Diego, USA) was 
used for all statistical analyses and graphs.
RESULTS
Whole-brain C26:0 concentration
Figure 1 shows the concentrations of C26:0 in the 
whole brains of rats in each of the 8 studied groups. 
Rats that received an intraperitoneal injection of C26:0 
in lecithin vesicles and were sacrificed after 45 minutes 
presented higher brain C26:0 levels when compared 
to the other groups (F[7,40] = 8.08, p < 0.0001).
Figure 1: C26:0 concentrations in the rats’ whole brains. 
Results represent mean ± standard error of the mean (SEM).
***p < 0.001 compared to the basal control group. ###p < 0.001 
compared to the saline control group.  & & &p < 0.001 compared 
to the lecithin vesicle (15 min) group. $$$p < 0.001 compared to 
the lecithin vesicle (45 min) group. §§§p < 0.001 compared to the 
vesicle + C26 (15 min) group. +p < 0.05 compared to the vesicle + 
C26 (45 min) group. One-way analysis of variance (ANOVA), 
followed by a Tukey’s post-hoc test.
Behavioral tests
Results of the open field task are displayed in 
Figure 2. Figure 2a shows reduced locomotion 
and exploratory capabilities (represented by fewer 
crossings) in rats that received the C26:0 and lecithin 
vesicle injection and were sacrificed after 45 minutes 
when compared to other groups (F[7,40] = 10.74, 
p < 0.0001]. Figure 2b corroborates these results by 
showing that the same animals presented a higher 
latency to initiate locomotion (expressed in seconds) 
compared to other groups (F[7,38] = 6.59, p < 0.0001]. 
Similarly, Figure 2c shows that rats belonging to this 
group presented reduced orienting and investigatory 
responses (measured by the number of rearing 
episodes) (F[7,40] = 5.41, p < 0.0001). Figure 2d 
illustrates the number of anxiety manifestations 
(grooming); no significant differences were observed 
in this behavioral aspect among the 8 studied groups 
(F[7,40] = 0.67, p > 0.05).
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Figure 2: Open field tasks. A: Crossings; B: Latency to initiate locomotion; C: Rearing; D: Grooming.
**p < 0.01 and ***p < 0.001 compared to the basal control group. ##p < 0.01 and ###p < 0.001 compared to the saline control group.  &p < 0.05 
and  & & &p < 0.001compared to the lecithin vesicle (15 min) group. $p < 0.05 and $$$p < 0.001 compared to the lecithin vesicle (45 min) group. 
@p < 0.05, @@p < 0.01, and @@@p < 0.001 compared to the lecithin vesicle (60 min) group. §p < 0.05 and §§p < 0.01 compared to the vesicle + 
C26 (15 min) group. +++p < 0.001 compared to the vesicle + C26 (45 min) group. Results represent mean ± standard error of the mean (SEM). 
One-way analysis of variance (ANOVA), followed by a Tukey’s post-hoc test.
DISCUSSION
X-ALD is an inborn error of the peroxisome 
metabolism characterized by a progressive demyelination 
of the brain’s white matter and adrenal insufficiency. 
Mutations in the ABCD1 gene result in several 
phenotypic variants that vary in aspects such as age 
of onset, rate of disease progression, and primary 
affected tissues. Although the mechanisms related to 
tissue damage are poorly understood, it is believed 
that the main accumulated metabolite (C26:0) could 
contribute, at least in part, to the pathophysiology of 
this disease. In this work, we investigated whether 
excess C26:0, administrated by intraperitoneal injection, 
might induce behavioral changes in male Wistar rats.
Here, we presented compelling evidence that a 
lecithin vesicle enriched with C26:0 was able to reach 
the brain, and that a peak in C26:0 concentration was 
verified in rats sacrificed 45 minutes after injection 
in comparison to the other groups. Figure 1 shows 
that C26:0 concentration is significantly higher in 
the “vesicle + C26” group sacrificed 45 minutes 
after injection when compared to the other groups, 
especially considering those animals sacrificed after 
15 or 60 minutes. In addition, C26:0 concentrations 
in animals sacrificed after 1 hour decreased again 
and were similar to the other groups, illustrating 
the kinetics of acid concentration. This probably 
occurred because the fatty acid was oxidized inside 
the peroxisome, since the rats used in this study 
were not knockouts and did not have a dysfunction 
in the ABCD1 gene. According to the literature, 
surprisingly, no detectable elevations in plasmatic 
concentrations of C24:0 or C26:0 were detected in 
X-ALD knockout mice, and this was in line with our 
results (data not shown)14. Furthermore, the same 
authors reported a 5-fold increase in C26:0 levels in 
the brain of knockout rats compared to other tissues. 
In this work, we verified that Wistar rats that received 
an intraperitoneal administration of C26:0 and were 
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sacrificed after 45 minutes presented a mean brain 
C26:0 level of 1.37 µmol/L, which would approach 
plasmatic levels of male X-ALD patients. In humans, 
X-ALD is usually diagnosed by measuring VLCFA 
levels in plasma13; male patients present a mean range 
of 1.36-4.94 µmol/L of C26:0, female heterozygotes 
have a mean range of 1.41-2.33 µmol/L, and healthy 
individuals present a mean range of 0.11-0.96 µmol/L15.
Behavioral tests are important in biomedical 
research for testing novel treatments, investigating 
currently used drugs, and in mechanistic studies. 
The open field task is one of the most commonly 
used tests for measuring animal behaviors. It is a 
fast and relatively easy test that provides a variety 
of behavioral information ranging from the subject 
animal’s general ambulatory ability to its emotionality16. 
We performed the open field test and assessed 
the number of crossings and grooming and rearing 
episodes, and measured the latency to locomotion. 
Results indicated that Wistar rats injected with C26:0 
developed an acute impairment of the central nervous 
system, since they presented a delay in initiating 
locomotion, decreased exploratory capabilities, and 
reduced orienting and investigatory responses.
It is important to highlight that these changes were 
observed in rats sacrificed 45 minutes after C26:0 
injection, suggesting that these results express the 
kinetics of acid degradation since the effects were still 
not pronounced in rats sacrificed after 15 minutes. 
Figure 2a illustrates that rats injected with C26:0 
and sacrificed after 45 minutes performed fewer 
crossings when compared to the control groups 
and to the group that received lecithin injection and 
was sacrificed after 45 minutes. Similarly, when 
observing latency to initiate locomotion, we noted 
that animals belonging to the “vesicle + C26 - 45 min” 
group presented a higher latency time to move when 
compared to the control groups and to the group 
that received lecithin alone and was sacrificed after 
45 minutes. By analyzing these two tests, we can 
clearly note the exclusive effect of C26:0 on the rats’ 
behavior and also affirm that lecithin (the vehicle 
component of the vesicles) had no influence on the 
results. Considering the rearing episodes, Figure 2c 
shows that rats in the “vesicle + C26 - 45 min” group 
presented fewer events when compared to the “lecithin 
vesicle - 15 min,” “lecithin vesicle - 60 min,” and 
“vesicle + C26 - 15 min” groups. When analyzing the 
test results of animals in the “vesicle + C26 - 60 min” 
group, it is possible to infer that the acid had already 
been oxidized 1 hour after the injection, because 
the behavior tended to be restored in comparison 
to the “vesicle + C26 - 45 min” group. Moreover, 
Figure 2d (number of grooming episodes) shows 
that no significant differences were observed among 
the 8 studied groups; that is, the rats presented no 
differences in anxiety manifestations.
The work performed by Pujol and colleagues17 
corroborated our results concerning behavioral 
alterations. Their study has shown that older ALD-
deficient mice (knockout) exhibited an abnormal 
neurological and behavioral phenotype, starting 
at approximately 15 months of age. Additionally, 
X-ALD-mutant rats at 20 months of age showed 
severe impairment in motor coordination abilities 
(verified by a rotarod test) and presented a significant 
reduction in exploratory activities or hypoactivity 
during an open field test. The authors related these 
behavioral effects with a slower nerve conduction 
and with myelin and axonal anomalies detected in 
the spinal cord and sciatic nerve, which correspond 
to what is observed in patients with AMN.
However, as opposed to the work performed by 
Pujol and colleagues17, the rats used in our work 
were young (2-3 weeks of age) and had not yet 
reached sexual maturity. We might presume that 
the administration of C26:0 in healthy rats induces 
behavioral changes that are similar to those of a 
child presenting the initial symptoms of the disease, 
considering that the earliest CCER symptoms frequently 
include cognitive dysfunction manifested as behavioral 
disturbances. In order to further complement our 
work, more studies would be needed to confirm our 
hypothesis; for instance, a neuroimaging study of the 
Wistar rats’ brains, or increased numbers of C26:0 
injections and time periods between injection and 
sacrifice for simulating disease chronicity.
Altogether, our data demonstrates for the first 
time in the literature that C26:0, by itself, can induce 
behavioral alterations in young Wistar rats at the 
motor capacity level, in an acute time of 45 minutes 
after C26:0 injection. These results are preliminary, 
but extremely important and promising for future studies 
of X-ALD pathophysiology and for understanding 
the relationship between C26:0 accumulation and 
locomotor impairment in human patients.
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